{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:41:32Z","timestamp":1778942492555,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Microbiology and Immunology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After eradication and containment of wild poliovirus (PV) and cessation of oral polio vaccinations, it is critical to minimize the risk of reintroducing PV into PV\u2010free communities via facilities that handle the virus. The potential risk of unintentional PV propagation through unidentified contaminated materials is a serious issue. This study reports the generation of HeLa and RD\u2010A cells deficient in functional <jats:italic>CD155<\/jats:italic> gene (\u2206PVR cells); these cells are not susceptible to PV but remain susceptible to other picornaviruses. These \u2206PVR cells will minimize the risk of unintentional transmission of PV and support performing the experiments more safely.<\/jats:p>","DOI":"10.1111\/1348-0421.12843","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T07:51:04Z","timestamp":1600069864000},"page":"835-839","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The risk of unintentional propagation of poliovirus can be minimized by using human cell lines lacking the functional <i>CD155<\/i> gene"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2745-5254","authenticated-orcid":false,"given":"Satoshi","family":"Koike","sequence":"first","affiliation":[{"name":"Neurovirology Project Tokyo Metropolitan Institute of Medical Science  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"WHO. Global polio eradication initiative. Available from:http:\/\/polioeradication.org\/"},{"key":"e_1_2_6_3_1","unstructured":"WHO. Global eradication of wild poliovirus type 2 declared. Declaration further milestone for globally\u2010coordinated vaccine switch in 2016 [cited 2015 Sep 20]. Available from:http:\/\/polioeradication.org\/news-post\/global-eradication-of-wild-poliovirus-type-2-declared\/"},{"key":"e_1_2_6_4_1","unstructured":"WHO. Two out of three wild poliovirus strains eradicated. Global eradication of wild poliovirus type 3 declared on World Polio Day 2019. [cited 2019 Oct 24]. Available from:http:\/\/polioeradication.org\/news-post\/two-out-of-three-wild-poliovirus-strains-eradicated\/"},{"key":"e_1_2_6_5_1","unstructured":"WHO. WHO global action plan to minimize poliovirus facility\u2010associated risk after type\u2010specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use: GAPIII.2015. [cited 2015 May]. Available from:https:\/\/apps.who.int\/iris\/handle\/10665\/208872"},{"key":"e_1_2_6_6_1","unstructured":"WHO. Guidance for non\u2010poliovirus facilities to minimize risk of sample collections potentially infectios for polioviruses.2018. [cited 2018 Mar]. Available from:http:\/\/polioeradication.org\/wp-content\/uploads\/2018\/04\/polio-containment-guidance-for-non-poliovirus-facilities-20180410-en.pdf"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90690-9"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb07520.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.32.5.1366-1368.1994"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199906)58:2<188::AID-JMV15>3.0.CO;2-H"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.11.6825-6832.1995"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)37212-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.10.4104"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.98.4.1194"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.03.019"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1992"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5304.1320"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"e01780\u201019","DOI":"10.1128\/mBio.01780-19","article-title":"Identification of the cell\u2010surface protease ADAM9 as an entry factor for encephalomyocarditis virus [published online ahead of print August 13, 2019]","volume":"10","author":"Baggen J","journal-title":"mBio"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"e02734\u201018","DOI":"10.1128\/mBio.02734-18","article-title":"A disintegrin and metalloproteinase 9 domain (ADAM9) is a major susceptibility factor in the early stages of encephalomyocarditis virus infection [published online ahead of print February 5, 2019]","volume":"10","author":"Bazzone LE","journal-title":"mBio"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"e00681\u201018","DOI":"10.1128\/JVI.00681-18","article-title":"Amino acid variation at VP1\u2010145 of enterovirus 71 determines attachment receptor usage and neurovirulence in hHuman scavenger receptor B2 transgenic mice","volume":"92","author":"Kobayashi K","year":"2018","journal-title":"J Virol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/jvi.64.4.1573-1583.1990","article-title":"Complete nucleotide sequence of infectious Coxsackievirus B3 cDNA: two initial 5\u2032 uridine residues are regained during plus\u2010strand RNA synthesis","volume":"64","author":"Klump WM","year":"1990","journal-title":"J Virol"}],"container-title":["Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1348-0421.12843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1348-0421.12843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1348-0421.12843","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1348-0421.12843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T10:24:18Z","timestamp":1693736658000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1348-0421.12843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/1348-0421.12843"],"URL":"https:\/\/doi.org\/10.1111\/1348-0421.12843","archive":["Portico"],"relation":{},"ISSN":["0385-5600","1348-0421"],"issn-type":[{"value":"0385-5600","type":"print"},{"value":"1348-0421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"2020-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}